Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5
Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $12 to $5.
Read original at benzingaStocks · News reference
BioHarvest Sciences Receives $1.4M Grant Approval From Israel Innovation Authority
BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 11:35 AM
- Checked
- Jul 15, 2026, 11:35 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.
Read original at benzingaConference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
Read original at benzingaBioHarvest Sciences shares are trading higher after the company reported Q2 financial results. The company revised its FY26 CDMO revenue guidance.
Read original at benzinga